May 27, 2008 - Angiomax (bivalirudin) significantly improved net clinical adverse events by 24 percent as well as resulted in a reduction in overall mortality by 32 percent and cardiac mortality by 38 percent when compared to heparin plus routine glycoprotein IIb/IIIa inhibitor (GPI) within 30 days following primary angioplasty strategy, according to results from the HORIZONS-AMI trial published in the New England Journal of Medicine.

May 26, 2008 – Spectranetics introduced the new LLD EZ Lead Locking Device (LLD) for the removal of nonfunctional or infected pacing and defibrillation leads, designed to enable physicians to secure the entire lead creating traction to enable the removal process.

May 27, 2008 - Cook Medical (Cook) has received approval from the FDA for its Zenith TX2 Thoracic TAA Endovascular Graft, marking the expansion of Cook Medical’s portfolio of devices to treat aortic diseases.

May 27, 2008 - Vascular Solutions will partner with Radius Medical Technologies for the U.S. launch of the MICRO Elite Snare, a device designed for the retrieval and manipulation of foreign bodies located in the coronary and peripheral cardiovascular system and the extra-cranial neurovascular anatomy, which Vascular Solutions will distribute exclusively in the U.S.

Cook Medical's Zenith TX2 Thoracic TAA Endovascular Graft is designed for thoracic endovascular aortic repair (TEVAR).

Vascular Solutions is partnering with Radius Medical Technologies to distribute in the U.S. the new MICRO Elite Snare, a device designed for the retrieval and manipulation of foreign bodies located in the coronary and peripheral cardiovascular system and the extra-cranial neurovascular anatomy.

May 22, 2008 - Nassir Marrouche, M.D., and his research team from the University of Utah School of Medicine received the Eric N. Prystowsky Fellow Clinical Research award for their abstract on experimental studies showing how magnetic resonance imaging (MRI) angiograms can be effectively used during atrial fibrillation (AF) procedures.

May 22, 2008 - MIV Therapeutics Inc. has enrolled the first patients in the registration trial of its VESTAsync polymer-free drug-eluting stent, as the company accelerates its timeline for the VESTASYNC II trial after positive nine-month human safety and efficacy data were reported in March at the American College of Cardiology meeting.

Medtronic introduced Profile 3D Annuloplasty Ring with a design based on the geometry of the saddle-shaped human mitral annulus to promote natural function with the aim of repairing rather than replacing a failing mitral valve.

The Profile 3D ring design is based data strongly suggesting that nature conserves the saddle-shaped annulus for a mechanical benefit. Specifically, leaflet stress can be related to saddle height, which could affect long-term durability of the repair.

May 21, 2008 - Hospitals are increasingly using real-time locating systems (RTLS) so clinicians know where to find the equipment they need or patients at any moment on a computerized map of the hospital. There are several technologies for RTLS tracking that use radio frequency identification (RFID), ultrasound or infrared emitting tags that are detected on a wireless network.
Subscribe to
© Copyright Wainscot Media. All Rights Reserved.
Subscribe Now